Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Otic neural progenitors · 1 trial · 3 indications
Frequency and severity of AEs considered related to Rincell-1 alone, the procedure used to administer Rincell-1, and to the CI device and/or the administered concomitant NIMP regime.
| Arm | Type | Description |
|---|---|---|
| Standard Care Unilateral CI + Rincell-1 | EXPERIMENTAL | Routine unilateral cochlear implantation with simultaneous single dose of Rincell-1 |
| Standard Care Unilateral CI only | ACTIVE_COMPARATOR | Routine unilateral cochlear implantation only |
| Name | Type | Description |
|---|---|---|
| Otic neural progenitors | DRUG | Advanced Cell Therapy - tissue engineered product |
| cochlear implantation | DEVICE | cochlear implant |
Inclusion Criteria: Cohort 1 Only 1. Aged 60-74 years (inclusive) at time of consent 2. Hearing Loss due to bilateral progressive presbycusis 3. Approved for unilateral cochlear implantation as per UK NICE criteria (TA566) 4. Documented threshold of ≥70dB in both ears at 1000, 2000 and 4000 Hz, an...
Otic neural progenitors, also known as Rincell-1, is an investigational small molecule being developed for sensorineural hearing loss. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
Otic neural progenitors, or Rincell-1, is a small molecule designed to address sensorineural hearing loss. The specific molecular target has not been disclosed, but the therapy is being studied in patients with cochlear implants to evaluate its potential to restore or improve auditory function.
Otic neural progenitors, also known as Rincell-1, is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker symbol YCBD. The company is conducting a Phase 1 clinical trial to evaluate the therapy in adults with cochlear implants.
Otic neural progenitors, or Rincell-1, is in Phase 1 clinical development. It is an investigational therapy and has not received FDA approval. The ongoing Phase 1 trial is a first-in-human study designed to assess the safety and preliminary efficacy of the treatment.
Otic neural progenitors, or Rincell-1, is being evaluated in a Phase 1 clinical trial registered as NCT07032038. This first-in-human, randomized, active-controlled study is enrolling 20 adults with cochlear implants in the United Kingdom, with conditions including sensorineural hearing loss, presbyacusis, and auditory neuropathy.
Yes, Otic neural progenitors is also known as Rincell-1. The therapy is being developed under this alternative name in clinical trial records, including the Phase 1 study NCT07032038, which evaluates Rincell-1 in adults with cochlear implants.